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ABSTRACT
The DKK1 gene encodes an extracellular inhibitor of the Wnt pathway with an important role in bone tissue development, bone
homeostasis, and different critical aspects of bone biology. Several BMD genome-wide association studies (GWASs) have consistently
found association with SNPs in the DKK1 genomic region. For these reasons, it is important to assess the functionality of coding and
regulatory variants in the gene. Here, we have studied the functionality of putative regulatory variants, previously found associated
with BMD in different studies by others and ourselves, and also six missense variants present in the general population. Using a Wnt-
pathway-specific luciferase reporter assay, we have determined that the variants p.Ala41Thr, p.Tyr74Phe, p.Arg120Leu, and p.Ser157-
Ile display a reduced DKK1 inhibitory capacity as compared with WT. This result agrees with the high-bone-mass (HBM) phenotype of
two women from our cohort who carried mutations p.Tyr74Phe or p.Arg120Leu. On the other hand, by means of a circularized chro-
mosome conformation capture- (4C-) sequencing experiment, we have detected that the region containing 24 BMD-GWA variants,
located 350-kb downstream of DKK1, interacts both with DKK1 and the LNCAROD (LncRNA-activating regulator of DKK1, AKA
LINC0148) in osteoblastic cells. In conclusion, we have shown that some rare coding variants are partial loss-of-function mutations
that may lead to a HBM phenotype, whereas the common SNPs associated with BMD in GWASs belong to a putative long-range reg-
ulatory region, through a yet unknownmechanism involving LNCAROD. © 2020 The Authors. JBMR Plus published byWiley Periodicals
LLC on behalf of American Society for Bone and Mineral Research.
KEY WORDS: WNT/β-CATENIN/LRPs; CELLS OF BONE OSTEOBLASTS; BONE DISEASES AND DISORDERS; OSTEOPOROSIS; GENETIC RESEARCH; MOLEC-
ULAR PATHWAYS REMODELING
Introduction
For the last two decades, genome-wide association studies(GWASs) have been a powerful tool to identify genes associ-
ated with complex diseases. Regarding osteoporosis, more than
500 loci associated with BMD have been determined. However,
these loci only explain 20% of the BMD variability; few have been
attributed a clear functional mechanism.(1) The challenge of cur-
rent genetics is to establish the underlying functional basis of all
these associations.
One of the most enriched pathways in genome-wide signifi-
cant signals for BMD is the Wnt pathway. Polymorphisms in sev-
eral of its genes have been associated with BMD and fracture
risk.(1–10) Moreover, rare and penetrant mutations causing Men-
delian bone phenotypes have been described in Wnt pathway
genes, such as the loss-of-function and gain-of-function muta-
tions in the LRP5 coreceptor, causing the two diametrically
opposed phenotypes of osteoporosis-pseudoglioma syn-
drome(11) and high bone mass (HBM),(12–14) respectively. The
Wnt pathway is finely regulated by several extracellular inhibi-
tors, amongwhich sclerostin and DKK1 stand out. These two pro-
teins prevent the formation of the heterotrimeric complex
LRP5/6-FZD-Wnt(15) by forming other heterotrimeric complexes,
together with LRP5 and LRP4 (in the case of sclerostin)(16,17) or
with LRP5 and Kremen1/2 (in the case of DKK1).(18) DKK1 binds
both the first and third β-propeller domains of LRP5,(19,20) and
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Received in original form September 21, 2020; accepted October 3, 2020. Accepted manuscript online October 7, 2020.
Address correspondence to: Susanna Balcells, Department of Genètica, Microbiologia i Estadística, Facultat Biologia, Av. Diagonal, 643, 08028 Barcelona, Spain.
E-mail: sbalcells@ub.edu
JBMR® Plus (WOA), Vol. 4, No. 12, December 2020, e10423.
DOI: 10.1002/jbm4.10423
© 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
1 of 9 n
it is in the first β-propeller domain where mutations causing the
HBM phenotype are clustered.(21–23) Different studies have
highlighted the important role of the DKK1 protein in the devel-
opment of skeletal tissue, in bone homeostasis and in different
critical aspects of bone biology.(15,24,25) In mice, the homozygous
Dkk1 KO is lethal at birth and displays severe defects in head for-
mation that result in anterior truncations.(26) In contrast, the het-
erozygous KO, the hypomorphic (doubleridge), the tamoxifen
inducible at 7 weeks, or the osteolineage-specific mouse models
show an increase in BMD and an increase in bone
formation.(27–31) By studying the allelic combination of null or
doubleridge mice (Dkk1+/db; Dkk1+/−; Dkk1db/db; Dkk1db/−;
Dkk1−/−), a gene dose-dependent inverse correlation with
BMD was observed.(28,29) On the other hand, transgenic overex-
pression of the Dkk1 gene in osteoblasts produces a relative
decrease in the number of osteoblasts, thus producing a
decrease in bone formation.(32,33) In the last decade, thanks to
the direct effect on the inhibition of osteoblastogenesis and
the indirect activation of osteoclastogenesis, sclerostin and
DKK1 have become interesting targets for the anabolic treat-
ment of osteoporosis. In particular, monoclonal antibodies
against DKK1 stimulate bone formation in younger animals and
to a lesser extent in adult animals, and enhance fracture
healing.(34)
Given the importance of DKK1 in bone physiology and pathol-
ogy, it is essential to reach a comprehensive understanding of
the functional roles of the DKK1 variants. In a previous study,
we resequenced the transcribed regions and the intronic flanks
of the gene in two patient groups with opposed and extreme
BMD values from the Barcelona osteoporosis (BARCOS) cohort
of postmenopausal women, and found three interesting variants
in potentially functional regions: a rare missense variant
(rs149268042; p.Arg120Leu), a rare 30UTR (untranslated region)
variant (rs74711339), and a common variant predicted to affect
splicing (rs1569198), which was also found nominally associated
with femoral neck BMD in the complete cohort.(35) In addition to
these variants, a region between DKK1 and MBL2 is relevant
because many GWASs on BMD found strong associations with
SNPs clustered in it and not with SNPs inside the DKK1
gene.(1,3–5,36–41)
In this study, our objective was to test the underlying func-
tionality of selected variants found in DKK1, as well as to deter-
mine if the region harboring the genome-wide significant SNPs
is actually regulating the DKK1 gene, the MBL2 gene, or both.
We carried out functional studies specific for each variant
(Fig. 1), and a 4C-seq experiment to study a GWA-significant
SNP-rich region. With this, we determined that the missense var-
iants p.Ala41Thr, p.Tyr74Phe, p.Arg120Leu, and p.Ser157Ile
reduce the DKK1 inhibitory capacity, and that the GWA-SNP
region is indeed interacting with DKK1 and also with the neigh-
boring lncRNA LNCAROD (AKA LINC0148) gene.
Materials and Methods
Cell culture
The human osteosarcoma cell line Saos-2 was used for luciferase
reporter assays and 4C-seq assays. It was obtained from the
American Type Culture Collection (ATCC HTB-85) and grown in
DMEM (Sigma-Aldrich, St. Louis, MO, USA), supplemented with
10% FBS (Gibco–Life Technologies, Grand Island, NY, USA) and
1% penicillin/streptomycin (p/s; Gibco–Life Technologies), at
37C and 5% of CO2. The human fetal osteoblast 1.19 (hFOB) cell
line and human medulla-derived mesenchymal stem cells
(MSCs) were used for 4C-seq assays. The hFOB 1.19 cell line
was obtained from ATCC (ATCC CRL-11372) and grown in
DMEM:F12 (1:1) medium without phenol red (Gibco–Life Tech-
nologies), supplemented with 10% FBS and 0.3 mg/mL geneticin
(Gibco–Life Technologies) at 34C and 5% of CO2. MSCs were
kindly provided by Dr. José Manuel Quesada Gómez from Insti-
tuto Maimónides de Investigación Biomédica, Hospital Universi-
tario Reina Sofía, Córdoba, Spain.(42) These cells were grown in
α-MEM medium (Gibco–Life Technologies), supplemented with
10% FBS, 1% p/s, and 1x glutamax (Gibco–Life Technologies) at
37C and 5% of CO2. Human primary osteoblasts (hOBs) used
for expression quantitative trait loci (eQTLs) assays are described
in Roca-Ayats and colleagues.(43)
Luciferase reporter constructs and DKK1 site-directed
mutagenesis
The mouse Wnt1-V5 expression vector, mesdc2 expression vec-
tor, human WT LRP5 expression vector, pRL-TK, pGL3-OT
reporter, and humanDKK1-FLAG expression vector are described
in Balemans and colleagues.(44) The mutations p.Ala41Tyr, p.
Tyr74Phe, p.Pro84Leu, p.Ala106Thr, p.Arg120Leu, and p.Ser157-
Ile were introduced into the expression vector DKK1-FLAG using
the QuickChange Site-Directed Mutagenesis kit (Agilent Tech-
nologies, Santa Clara, CA, USA), following the manufacturer’s
instructions. A 300-bp fragment of the DKK1 30UTR containing
the SNP rs74711339 in a central position was cloned (in each of
the two allele versions) into the pmirGLO dual-luciferase miRNA
target expression vector (Promega, San Luis Obispo, CA, USA).
Constructs were cloned using the XhoI and SdaI restriction sites.
All primers used are detailed in Supplementary Information
Table S1. In all cases, the presence of point mutations and
absence of errors were verified through Sanger sequencing.
Luciferase gene reporter assay
Two luciferase gene reporter assays were performed: one to test
the inhibitory activity of WT andmutant DKK1 proteins (Wnt path-
way reporter assay) and the other to test the effect of the 30UTR
variant rs74711339 (30UTR reporter assay). For both experiments,
3 × 105 Saos-2 cells per well were cultured in 6-well plates,
24 hours before the transfection. For the Wnt pathway reporter
assay, we cotransfected: mouse Wnt1-V5 (64 ng), mesdc2
(128 ng), human WT LRP5 (128 ng), pRL-TK (160 ng), pGL3-OT
reporter (1600 ng). and DKK1 (48 ng). When necessary, the empty
pcDNA3 vector was used to equalize the total amount of DNA
transfected in each experiment (total DNA = 2128 ng). For the
miRNA reporter assay, we transfected at a 1:1 ratio, the pGFP vector
and either the empty pmirGLO or with the DKK1-30UTR fragment
with one or the other allele (total DNA =1.6 μg). Fugene HD was
used following the manufacturer’s instructions. Forty-eight hours
after transfection, cells were lysed and the luciferase activities of
Photinus pyrali and Renilla reniformis were measured using a Glo-
max Multi + luminometer (Promega), following the instructions
of the dual-luciferase reporter assay system (Promega).
Western blot assay
For the Western blot assay, 3 × 105 Saos-2 cells per well were cul-
tured in 6-well plates, 24 hours before the transfection. We trans-
fected 2 μg of the DKK1 expression plasmid (WT or the missense
variant: p.Ala41Thr, p.Tyr74Phe, p.Pro84Leu, p.Ala106Thr, p.
Arg120Leu, p.Ser157Ile). For the negative control, we transfected
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2 μg of the empty pcDNA3 vector. Fugene HDwas used following
the manufacturer’s instructions. After 24 hours, the medium was
changed, reducing from 2 to 1 mL of DMEM, without FBS or anti-
biotics. Forty-eight hours after transfection, the supernatant (con-
ditioned medium) of each condition was collected and were
concentrated using 10 K Amicon Ultra filters (Millipore, Watford,
UK). Extracellular proteins (concentrated conditioned medium)
were quantified using the Pierce BCA Protein Assay kit (Thermo
Fisher Scientific, Waltham, MA, USA). Proteins from concentrated
conditionedmedium (5 μg/lane) were separated by electrophore-
sis in an SDS-PAGE and transferred to a hydrophobic polyvinyli-
dene fluoride transfer membrane (Millipore). The ab109416
antibody against DKK1 (Abcam, Cambridge, UK) was used. The
imageswere developedusing aperoxidase-conjugated secondary
antibody (anti-rabbit IgG; A0545) for DKK1 antibody. All the exper-
imentswere performed in three independent biological replicates.
eQTL assay
DNA was extracted from cultured hOBs using the Wizard Geno-
mic DNA Purification kit (Promega), according to the manufac-
turer’s instructions. The concentration of the purified DNA was
analyzed on a spectrophotometer (NanoDrop; Thermo Fisher
Scientific). Genotypes for rs1569198, rs74711339, and
rs1373004 were assessed by Sanger sequencing using the Big-
Dye Terminator v3.1 (Applied Biosystems, Warrington, UK) in
the genomics facilities of the Universitat de Barcelona. Primers
(Invitrogen, Carlsbad, CA, USA; Thermo Fisher Scientific) were
designed using the Primer3 Input 0.4.0 (Supplementary Informa-
tion Table S1). RNA was extracted from cultured hOBs using the
High Pure RNA Isolation kit (Roche Diagnostics, Mannheim, Ger-
many), according to the manufacturer’s instructions. RNA was
quantified using a NanoDrop spectrophotometer and retrotran-
scribed using the High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems, Thermo Fisher Scientific), according to the
specifications of the manufacturer. qPCR was performed using
UPL probes (Roche) on a LightCycler 480 Instrument II (Roche).
HMBS gene expression was used as normalizing control, and fold
changes were calculated by relative quantification, using the
second derivative method. Primers are summarized in Supple-
mentary Information Table S1.
Alternative splicing analysis
hOB cDNA from homozygous women for the rs1569198 SNP was
amplified using two primers (Fw: TCCGAGGAGAAATTGAGGAA
and R: TCCATGAGAGCCTTTTCTCC). The forward primer is located
at the 30end of exon 3 and the reverse primer is located at the 50
end of exon 4. This pair of primers would amplify a 254-bp ampli-
con in the case of WT splicing, and a 296-bp amplicon in the case
of alternative splicing.
Circularized chromosome conformation capture
sequencing
Circularized chromosome conformation capture-sequencing
(4C-seq) experiment was carried out at the Functional Genomics
Service of the Centro Andaluz de Biología del Desarrollo (Sevilla,
Spain). 4C-seq libraries were generated from Saos-2, hFOB 1.19
and hMSC cell lines as described previously.(45,46) 4-bp cutters
were used as primary (DpnII) and secondary (Csp6I) restriction
enzymes. For each cell line, a total of 1.6 μg of library was PCR
amplified (primers used: AGTAAGCTGTGGAATCAATGAC and
CTGAGCCTCTCTTCTCGGATC, chr10:54427977–54428133, GRCh
37). Samples were sequenced with Illumina Hi-Seq technology
according to standard protocols at the Genomics Service of the
Centro Nacional de Investigaciones Cardiovasculares (CNIC,
Madrid, Spain). 4C-seq data were generated as described previ-
ously.(47) Briefly, raw sequencing data were demultiplexed and
mapped to the corresponding reference genome (GRCh37).
Reads located in fragments flanked by two restriction sites of
the same enzyme, in fragments smaller than 40 bp or within a
window of 10 kb around the viewpoint were filtered out. 4C-
seq data were normalized by the total weight of reads within
2 Mb around the viewpoint.
4C-seq data were analyzed with the AFourC software (publicly
available at https://github.com/Nikoula86/AFourC.git), following
and adapting previously described pipelines.(48–50) Briefly, we
Fig 1. Scheme of the DKK1 gene including coding exons (boxes), introns (lines), 50 and 30UTR (small boxes) and the location of all the variants tested.
Experiments performed to test the functionality of each type of variant are indicated below the scheme. eQTL = Expression quantitative trait loci; miRNA
= microRNA; UTR = untranslated region.
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assumed that the 4C signal profile relative to the viewpoint v
with coordinate xv on chromosome N is formed by three inde-
pendent contributions: a constant background level, a negative
exponential representing the monotonic decay of the 4C signal
with the genomic distance from the viewpoint,(50) and
N gaussians representing the interaction peaks:
S4C xð Þ= B+ Ixv  e− x−xvð Þ=λ +
XN
i = 1
P xið Þ e− x−xið Þ
2
= 2σ2ð Þ
To estimate the genomic distance-dependent monotonic
decay, we assumed a symmetric trend around the viewpoint
and performed the exponential fit on the left–right averaged
profile. Statistically significant peaks were detected using a
p value of 0.0005.
Statistical methods
Wnt pathway assay
The ratio of the Firefly and Renilla luciferase measurement was
calculated (relative luciferase units; RLUs). For each mutant, the
test factor had the following levels: Empty (refers to the lucifer-
ase activity resulting from the endogenous Wnt pathway), Active
(luciferase activity produced by theWnt pathway in the presence
of exogenousWnt1, medc2, and LRP5), Inhibitor (luciferase activ-
ity in the presence of exogenous Wnt1, mesdc2, LRP5, and WT
DKK1 inhibitor), and Mutant (luciferase activity in the presence
of exogenous Wnt1, mesdc2, LRP5, and each of the mutant
DKK1 proteins). We analyzed the data distribution and hetero-
scedasticity via the Shapiro-Wilk test for normality and the
Breusch-Pagan test, respectively. We normalized replicates per
day using the DKK1-WT inhibition to reduce the nuisance factor.
Then, we assessed the differences between luciferase activities
through the Kruskal-Wallis test. A post hoc test for multiple com-
parisons of groups was performed according to pairwise com-
parisons using the Wilcoxon rank sum test, adjusting p values
with Bonferroni. Statistical analyses were performed using R soft-
ware v. 3.5.3 (R Foundation for Statistical Computing, Vienna,
Austria; https://www.r-project.org/), and p < 0.05 was consid-
ered significant. GraphPad (GraphPad Prism 8; GraphPad Soft-
ware, La Jolla, CA, USA) was used for graphic representation.
Each experiment included a minimum of three replicates and
was repeated independently in three separate experiments.
30UTR assay
The ratio of the Firefly and Renilla luciferase measurement was
calculated (RLUs). We analyzed the data distribution and homo-
geneity of variances via the Shapiro-Wilk test for normality and
the Bartlett test, respectively. We normalized replicates per day
using the empty vector activity to reduce the nuisance factor.
We assessed the differences between luciferase activities
through an ANOVA test. The Tukey HSD (honestly significant dif-
ference) test was used to perform the post hoc test for multiple
group comparisons, testing the effect between all the conditions
in the miRNA assay. Statistical analyses were performed using R
software v. 3.5.3 (R Foundation for Statistical Computing), and
p < 0.05 was considered significant. GraphPad (Graphpad Prism
8) was used for graphic representation. Each experiment
included three replicates and was repeated independently in
four separate experiments.
eQTL assay
For the study of the eQTLs, the WGassociation function in R soft-
ware v.3.5.3 was used.(51) This function carries out an association
analysis between SNPs and a dependent variable (DKK1 expres-
sion levels) under five different genetic inheritance models:
codominant, dominant, recessive, overdominant, and log-
additive.
Results
Functional evaluation of six DKK1 missense variants
To measure the inhibitory activity of six mutant DKK1 proteins
(Fig. 1) on the canonical Wnt pathway, we performed a specific
luciferase reporter gene assay. The transfection ofWnt1, mesdc2,
and LRP5, together with a TCF/LEF-luciferase reporter, in Saos-2
cells resulted in an approximate fivefold stimulation of the
endogenous Wnt pathway as previously described.(22) Likewise,
addition of WT DKK1 resulted in a one-third inhibition of the
pathway (35.2%; Fig. 2). In contrast, addition of either of the four
DKK1 mutant proteins, p.Ala41Thr, p.Tyr74Phe, p.Arg120Leu,
and p.Ser157Ile, resulted in a significantly reduced inhibitory
capacity as follows: p.Ala41Thr displayed a 21.9% inhibition of
the fully stimulated Wnt pathway (37.8% loss of the inhibition
related to WT DKK1; p < 0.001), p.Tyr74Phe, a 23.2% inhibition
of the Wnt pathway (34% of WT DKK1; p < 0.001), p.Arg120Leu,
a 15.6% inhibition (55.2% of WT DKK1; p < 0.001), and p.Ser157-
Ile, a 22.2% inhibition (37% ofWT DKK1; p < 0.001). No significant
Fig 2. Luciferase reporter assays of six DKK1 missense variants. Boxplots
of the normalized relative luciferase activity (RLU) of the following trans-
fections: endogenous Wnt pathway (transfected only with the TCF/LEF
reporter construct and the empty pcDNA3 vector; Empty), activated path-
way (cotransfection: same as before plus Wnt1, LRP5 and mesdc2; Active)
and the pathway inhibited by either the WT DKK1 or the six mutated
DKK1 proteins (cotransfection as before plus the corresponding DKK1
constructs). Significant differences between the mutated DKK1 and the
WT DKK1 (used as normalizer) are indicated as ***p < 0.001. Error bars
represent the SD.
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differences were observed for the remaining two missense vari-
ants (Fig. 2). By performingWestern blot analyses of the different
DKK1 mutant proteins secreted to the extracellular space, we
observed that only the p.Ser157Ile mutant was expressed at
lower levels than those of WT DKK1. In contrast, all other mutants
were expressed at similar or higher levels compared to the WT
(Supplementary Information Fig. S1). Altogether, we have deter-
mined that four of the six missense variants do affect the DKK1
inhibitory capacity.
Functional evaluation of variants rs74711339 (30UTR) and
rs1569198 (intronic)
To test the functional activity of the DKK1-30UTR variant
rs74711339, we performed a 3’UTR-luciferase reporter assay in
Saos-2 cells. Significant differences were found between the
empty vector and either allele, whereas no significant differences
were detected between both alleles (Supplementary Informa-
tion Fig. S2). This result indicates that 30UTR of DKK1 is involved
in transcript expression or stabilization in Saos-2 cells, but the
SNP tested is not affecting this regulation.
Variant rs1569198 is located in intron 3, 43 nucleotides
upstream of the last exon of the gene. According to several in
silico predictors, the G allele would generate a new splicing
acceptor site (atgcaggtttagCA), producing a proteinwith 16 addi-
tional amino acids, encoded by the 30 end of intron 3. However,
this alternative transcript has not been detected in primary oste-
oblast cDNA from 12 women homozygous for the G allele
(Supplementary Information Fig. S3).
SNPs rs1569198 and rs74711339 are defined as eQTLs of DKK1
in adrenal gland and transformed fibroblasts, respectively,
according to GTEx (V8 release; Supplementary Information
Table S2). Because bone tissue is not available in this database,
we used an in-house collection of 45 primary osteoblasts to
determine whether these two SNPs (plus rs1373004, found asso-
ciated with BMD and risk of fracture in Estrada and colleagues(3))
are cis-eQTLs of DKK1 in these cells. None of the tested SNPs
resulted as eQTLs in our samples (Supplementary Information
Fig. S4).
Chromatin interaction from the GWAS hit locus
We tested if the region containing 24 BMD-GWAS SNPs, located
350-kb downstream of DKK1 (viewpoint, dashed gray line, in
Fig. 3), is actually regulating DKK1, MBL2, or both. We performed
a 4C-seq experiment in three types of bone-related cells (MSCs,
hFOB 1.19, and the Saos-2 osteosarcoma cell line), and we
applied an algorithm to discern the significant contacts (see
Materials and Methods; arched lines in Fig. 3). We only observed
interactions of this viewpoint with sequences included in a geno-
mic region spanning from 628 kb centromeric to the viewpoint
to 141 kb telomeric. No other interactions were detected else-
where in the genome. Inside this interval, we detected two main
significant interacting regions common to all three cell types.
The first one coincides with theDKK1 promoter; it is the strongest
signal detected. The second corresponds to an extended region
including several LNCAROD transcripts and enhancer signals
according to the GeneHancer database(52)(Fig. 3). No significant
interaction was detected with MBL2, except for an interaction
with sequences located several kb upstream of it in Saos-2 cells.
Altogether, we have concluded that the BMD-GWA-SNP-rich
region is interacting with both DKK1 and the lncRNA LNCAROD
in three bone-related cell types.
Discussion
In this work, we have studied the functionality of intragenicDKK1
variants and analyzed a region harboring a cluster of genome-
wide significant SNPs from different GWASs. We have
determined that four of six missense mutations affect the DKK1
inhibitory capacity. Additionally, we have determined that the
intergenic region containing the genome-wide significant sig-
nals interacts not only with DKK1, but also with the lncRNA
LNCAROD gene in bone cells.
Fig 3. 4C-seq using the SNP rs1373004 region as viewpoint in human
fetal osteoblast (hFOB 1.19), mesenchymal stem cells (MSCs), and
Saos-2 cell line. (A) Graphical representations of the read depths
(Interaction strength) across the DKK1-MBL2 genomic region. Significant
interactions are marked with arched lines and the color scale corre-
sponds to the strength of these significant interactions. (B) Genes in this
region: PRKG1 (ENST00000373980.4), PRKG1-AS1 (NR_038277.1), DKK1
(ENST00000373970.3), LNCAROD_1 (NR_120642.1), LNCARDOD_2
(NR_120641.1), and MBL2 (ENST00000373968.3) from GRCh37/hg19,
and in green the LNCAROD_3 (ENST00000443523) from GENCODE
V32.2 GRCh38/hg18. (C) Representation of the GeneHancer (GH) track
from UCSC genome browser (enhancers -gray- and promoters -red-).
(D) SNPs associated with bone parameters in different genome-wide
association studies (GWASs), extracted from the GWAS catalog (https://
www.ebi.ac.uk/gwas/).
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Missense variants
We have tested the functionality of six DKK1 missense variants.
Two of them were found in two women with HBM in previous
studies of our group, p.Try74Phe(53) and p.Arg120Leu(35) and five,
including the latter, are among the most frequent missense var-
iants in the general population according to gnomAD v3 (p.
Arg120Leu, p.Ala106Thr, p.Ser157Ile, p.Pro84Leu and p.
Ala41Thr). To test their possible functionality, we have per-
formed a luciferase reporter assay specific for the canonical
Wnt pathway and we have determined that mutations p.
Ala41Thr, p.Tyr74Phe, p.Arg120Leu and p.Ser157Ile affect DKK1
inhibitory capacity whereas p.Pro84Leu and p.Ala106Thr did
not. Interestingly, none of the variants tested are located in the
CRD2 domain (amino acids 189–263) known to bind to the
LRP5 first and third β-propeller to exert the inhibition (Fig. 4).
Variant p.Arg120Leu, which displays the strongest effect on
DKK1 inhibitory capacity (55.2%), is the consistently predicted
as deleterious, according the four most commonly used in silico
tools (Table 1). In a previous work,(35) we detected it in a woman
with HBM (sum Z-score = 6.20; menarche at 12 years; hysterec-
tomy at 33 years; chronic mild renal insufficiency, arterial hyper-
tension, and obesity). We propose that the loss-of-function of the
protein with the p.Arg120Leu mutation may be contributing to
the HBM phenotype of this woman, through insufficient inhibi-
tion of the Wnt pathway. In fact, this variant modifies the N-
terminal cysteine-rich domain (CDR1; Fig. 4), described to exert
independent signaling functions through other unknown recep-
tors or pathways.(55) The loss-of-function that we have observed
for this variant does not agree with the study by Korvala and
colleagues,(56) who did not find a lower inhibitory capacity for
the same mutated protein. Technical differences may explain
these negative results. In fact, these authors and others(56,57)
have found this mutation in patients with primary osteoporosis,
a phenotype that does not fit with the loss of function of DKK1
and diametrically opposed to the HBM phenotype of our patient.
Possible explanations for these discrepant findings may be a
reduced penetrance for this variant and differences in patients’
genetic background. Further investigation, preferably in vivo,
may resolve this discrepancy.
The p.Arg120Leu and also p.Ala41Thr have been described as
associated with type I Chiari disease (CMI).(58) This disease is
defined as a downward herniation of the cerebellar tonsils across
the foramen magnum caused by defects in the development of
the occipital bone and the posterior fossa, which produces a
neurologic dysfunction by direct compression of the neural tis-
sue in the craniovertebral junction.(59,60) Given the bone involve-
ment in CMI, it will be interesting to study the possible
relationship betweenmutations in DKK1 and this disorder, which
in many cases is asymptomatic and undiagnosed.
p.Ala41Thr is the variant with the second highest loss of inhib-
itory capacity (37.8%) and also predicted as deleterious by SIFT
software (Sorting Intolerant From Tolerant; available from:
https://sift.bii.a-star.edu.sg/; Table 1). This variant affects the
NAIKN motif (amino acids 40–44; Fig. 4), crucial for binding to
the first β-propeller of LRP5/6 proteins and present in all Wnt-
pathway inhibitors.(20) Its frequency in the general population
is 2.56 of every 10,000 individuals, but its effect in terms of bone
Fig 4. Domain structure of the DKK1 protein and position of the missense variants tested. The limits of the domains and the glycosylation sites (dots) are
indicated below the scheme of the protein, together with the LRP5/6 binding domains (NAIKN motif and CRD2). CRD = Cysteine-rich domain; SP = signal
peptide.
Table 1. Pathogenicity Predictions of the Six Missense Variants Tested
Mutations
In silico predictors
MAF (gnomAD v3) Loss of inhibitory capacity (%) Sign.SIFT PolyPhen-2 CADD REVEL
p.Arg120Leu D PD LD LDC 0.00282 55.2 *
p.Ala41Thr D B LB LB 0.000128 37.8 *
p.Pro84Leu T PssD LB LB 0.000088 — ns
p.Ser157Ile T B LB LB 0.000884 37.0 *
p.Try74Phe T B LB LB 0.0000201 34.0 *
p.Ala106Thr T B LB LB 0.00228 — ns
Loss of inhibitory capacity and significance (Sign.) according to the results presented in this article. B = benign; CADD = combined annotation depen-
dent depletion (available from: https://cadd.gs.washington.edu/; D = deleterious; gnomAD v3 = Genome Aggregation Database, version 3; LB = likely
benign; LD = likely deleterious; LDC = likely disease causing; PD = probably damaging; MAF = minor allele frequency; ns = nonsignificant; PolyPhen-
2 = polymorphism phenotyping version 2 (available from: http://genetics.bwh.harvard.edu/pph2/); PssD = possibly damaging; REVEL = rare exome variant
ensemble learner(54); SIFT = sorting intolerant from tolerant (available from: https://sift.bii.a-star.edu.sg/); T = tolerated.
*p < 0.001.
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mass is still unknown, as it happens for the p.Ser157Ile variant.
The latter also displayed lower inhibitory activity, but in this case
it may be a consequence of reduced secretion of the protein to
the extracellular space (Supplementary Information Fig. S1).
Finally, the variant p.Try74Phe was found in a previous study
cosegregating in a family with HBM,(53) and the functional effect
identified here is consistent with the cosegregation in the HBM
family.
30UTR and splicing variants
In contrast to missense variants, we were not able to find func-
tional evidence for variants rs74711339 and rs1569198, located
in the 30UTR and in intron 3, respectively. The effect of these var-
iants in other cell types or in different developmental stages can-
not be ruled out.
GWAS hit locus
A group of 30 SNPs associated with bone parameters in 10 differ-
ent GWASs exists in a 3.3-Mb window in 10q21.1,(1,3–5,36–41) of
which 24 are clustered within a 73-kb genomic region located
320 kb telomeric from DKK1 and 54 kb centromeric from MBL2
(Fig. 3D). However, no enhancer marks overlap with this region,
only two of these 24 SNPs are described as eQTLs (rs7088220
and rs12218358 forMBL2; GTEx v8) and no interactions between
this GWA-SNP–rich region and neighboring genes have been
reported. We undertook a 4C-seq assay to determine its interac-
tions across the genome in three bone cell types, and found that
the GWA-SNP–rich region is interacting with both DKK1 and
regions that harbor several newly described transcripts of
LNCAROD. Interestingly, this lncRNA has been recently shown
to enhance DKK1 transcription,(61) requiring chromosomal prox-
imity between the A-ROD and the DKK1 loci. Our 4C-seq data
are in agreement with these results because we found interac-
tions with both DKK1 and LNCAROD, which suggests a regulatory
role for the GWA-SNP–rich region. It should be noted that in the
study by Ntini and colleagues,(61) they only considered short
forms of LNCAROD, whereas the last build of the genome
(hg38) includes new longer versions, overlapping with the
GWA-SNP–rich region (see green lines in Fig. 3B). The regulatory
role of the GWA-SNP–rich region is further supported by the dou-
bleridge spontaneous mouse. This mouse model bears a 60-kb
deletion (located 150 kb from Dkk1 and 90 kb from Mbl2), prob-
ably corresponding to this human region, and displays a drastic
drop in Dkk1 expression levels (between 35% and <1% of WT),
while keeping the levels of neighboring Mbl2 and Prkg1 genes
intact.(28,29) In this sense, it would be interesting to verify if
LNCAROD is underexpressed in this mouse model, which would
confirm the role of this lncRNA in DKK1 regulation. Our results
clearly show for the first time that this region is relevant for the
regulation of DKK1, and it will be very interesting to assess the
specific role of the different SNPs in this process.
Limitations
This work has two main limitations. One of them is the complex
luciferase assay used for the study of missense mutations. This
method involves the cotransfection of several vectors, which
implies high variability. It is possible that some of the variants
tested, expected to have a small effect, show differences in activ-
ity below the sensitivity of the reporter gene assay we have used.
Regarding the eQTL study, the main limitation is the sample size.
Because of difficulties in obtaining appropriate samples, we only
were able to use 45 primary osteoblasts, which precluded testing
SNPs with low allele frequency. It would be useful to have a bank
of primary osteoblasts with a much higher sample size to get
information on different eQTLs important for bone; this informa-
tion is lacking in current databases.
Conclusions
In conclusion, for the first time we show functional evidence for
the relevance of DKK1 in HBM phenotype and osteoporosis
determination. Four missense variants in DKK1 affect its inhibi-
tory capacity, consistent with the HBM phenotype of a few indi-
viduals bearing these changes. Additionally, genomic
interactions exist between a region rich in BMD-GWA-SNP and
the DKK1 gene, and also with a lncRNA known to enhance
DKK1 expression. These functional data open a way to study
the mechanisms of DKK1 regulation, which may define novel
therapeutic targets for bone diseases.
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